expression tumour-specific antigens underlies cancer immunoediting 
cancer immunoediting process immune cells particularly lymphocytes adaptive immune system protect host development cancer alter tumour progression driving outgrowth tumour cells decreased sensitivity immune attack carcinogen-induced mouse models cancer shown primary tumour susceptibility thereby enhanced immune-compromised mice whereas capacity tumours grow transplantation wild-type mice reduced however many questions process cancer immunoediting remain unanswered part known antigenic complexity heterogeneity carcinogen-induced tumours adapted genetically engineered autochthonous mouse model sarcomagenesis investigate process cancer immunoediting system allows us monitor onset growth immunogenic non-immunogenic tumours induced situ harbour identical genetic histopathological characteristics comparing development tumours immune-competent mice development mice broad immunodeficiency specific antigenic tolerance show recognition tumour-specific antigens lymphocytes critical immunoediting sarcomas furthermore primary sarcomas edited become less immunogenic selective outgrowth cells able escape t lymphocyte attack loss tumour antigen expression presentation major histocompatibility complex necessary sufficient immunoediting process occur results highlight importance tumour-specific-antigen expression immune surveillance potentially immunotherapy 
